CPRX Stock Analysis: Catalyst Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 3.856m USD | 12M Return: 45% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 51.1M
EPS Trend: 81.6%
Qual. Beats: 3
Rev. Trend: 97.5%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
Catalyst Pharmaceuticals (NASDAQ: CPRX) is a US commercial-stage biopharmaceutical company headquartered in Coral Gables, Florida, that develops and commercializes therapies for patients with rare diseases. Its marketed products include Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), Fycompa for focal onset and tonic-clonic seizures, and AGAMREE, a corticosteroid approved for Duchenne muscular dystrophy.
The company has expanded its portfolio through in-licensing, holding agreements with BioMarin Pharmaceutical and a collaboration with Endo Ventures Limited covering a generic Sabril tablet program. As a mid-cap biotech focused on orphan and rare neurological disorders, Catalyst operates in a segment that often benefits from extended market exclusivity and premium pricing under the Orphan Drug Act, though the companys pipeline is concentrated around a small number of commercial assets.
- Firdapse sales growth drives revenue beat expectations
- AGAMREE launch accelerates in Duchenne muscular dystrophy market
- Patent exclusivity shields Firdapse from generic competition
| Net Income: 221.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA -11.30 > 1.0 |
| NWC/Revenue: 135.4% < 20% (prev 107.4%; Δ 27.98% < -1%) |
| CFO/TA 0.18 > 3% & CFO 208.2m > Net Income 221.3m |
| Net Debt (-753.2m) to EBITDA (334.7m): -2.25 < 3 |
| Current Ratio: 7.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (126.9m) vs 12m ago -0.04% < -2% |
| Gross Margin: 82.32% > 18% (prev 86.11%; Δ -3.79% > 0.5%) |
| Asset Turnover: 58.06% > 50% (prev 58.83%; Δ -0.77% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.70 (Total Current Assets 940.4m - Total Current Liabilities 132.4m) / Total Assets 1.15b |
| B: 0.46 (Retained Earnings 523.3m / Total Assets 1.15b) |
| C: 0.29 (EBIT TTM 296.5m / Avg Total Assets 1.03b) |
| D: 7.51 (Book Value of Equity 1.01b / Total Liabilities 134.9m) |
| Altman-Z'' = 15.92 = AAA |
| DSRI: 1.63 (Receivables 131.3m/72.3m, Revenue 597.0m/534.6m) |
| GMI: 1.05 (GM 86.11% / 82.32%) |
| AQI: 0.74 (AQ_t 0.18 / AQ_t-1 0.24) |
| SGI: 1.12 (Revenue 597.0m / 534.6m) |
| TATA: 0.01 (NI 221.3m - CFO 208.2m) / TA 1.15b) |
| Beneish M = -2.54 (Cap -4..+1) = A |
As of July 01, 2026, the stock is trading at USD 31.46 with a total of 1,617,250 shares traded. Over the past week, the price has changed by +0.25%, over one month by +0.74%, over three months by +32.30% and over the past year by +44.98%.
Current recommended Stop Loss: 31.20 (which is 0.8% or 1.9 ATR below the current price).
Catalyst Pharmaceuticals has received a consensus analysts rating of 4.86. Therefore, it is recommended to buy CPRX.
- StrongBuy: 6
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.7 | 0.7% |
P/E Trailing = 18.2081
P/E Forward = 12.9702
P/S = 6.4598
P/B = 3.8079
Revenue TTM = 597.0m USD
EBIT TTM = 296.5m USD
EBITDA TTM = 334.7m USD
Long Term Debt = 2.23m USD (estimated: total debt 2.68m - short term 446k)
Short Term Debt = 446k USD (from shortTermDebt, last quarter)
Debt = 2.68m USD (from shortLongTermDebtTotal, last quarter) (leases 2.68m already included)
Net Debt = -753.2m USD (calculated: Debt 2.68m - CCE 755.9m)
Enterprise Value = 3.10b USD (3.86b + Debt 2.68m - CCE 755.9m)
Interest Coverage Ratio = unknown (Ebit TTM 296.5m / Interest Expense TTM 0.0)
EV/FCF = 14.91x (Enterprise Value 3.10b / FCF TTM 208.1m)
FCF Yield = 6.71% (FCF TTM 208.1m / Enterprise Value 3.10b)
FCF Margin = 34.86% (FCF TTM 208.1m / Revenue TTM 597.0m)
Net Margin = 37.08% (Net Income TTM 221.3m / Revenue TTM 597.0m)
Gross Margin = 82.32% ((Revenue TTM 597.0m - Cost of Revenue TTM 105.5m) / Revenue TTM)
Gross Margin QoQ = 83.82% (prev 82.91%)
Tobins Q-Ratio = 2.70 (Enterprise Value 3.10b / Total Assets 1.15b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.68m)
Taxrate = 25.34% (75.1m / 296.5m)
NOPAT = 221.3m (EBIT 296.5m * (1 - 25.34%))
Current Ratio = 7.10 (Total Current Assets 940.4m / Total Current Liabilities 132.4m)
Debt / Equity = 0.00 (Debt 2.68m / totalStockholderEquity, last quarter 1.01b)
Debt / EBITDA = -2.25 (Net Debt -753.2m / EBITDA 334.7m)
Debt / FCF = -3.62 (Net Debt -753.2m / FCF TTM 208.1m)
Total Stockholder Equity = 935.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 21.52% (Net Income 221.3m / Total Assets 1.15b)
RoE = 23.65% (Net Income TTM 221.3m / Total Stockholder Equity 935.8m)
RoCE = 31.60% (EBIT 296.5m / Capital Employed (Equity 935.8m + L.T.Debt 2.23m))
RoIC = 22.45% (NOPAT 221.3m / Invested Capital 985.8m)
WACC = 8.75% (E(3.86b)/V(3.86b) * Re(8.76%) + D(2.68m)/V(3.86b) * Rd(0.0%) * (1-Tc(0.25)))
Discount Rate = 8.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.54 | Cagr: 4.92%
[DCF] Terminal Value 71.59% ; FCFF base≈231.9m ; Y1≈203.4m ; Y5≈164.3m
[DCF] Fair Price = 26.35 (EV 2.47b - Net Debt -753.2m = Equity 3.23b / Shares 122.4m; r=8.75% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 81.63 | EPS CAGR: 55.29% | SUE: 1.25 | # QB: 3
Revenue Correlation: 97.48 | Revenue CAGR: 26.87% | SUE: 0.27 | # QB: 0
EPS next Quarter (2026-09-30): EPS=0.82 | Chg30d=+12.09% | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=3.17 | Chg30d=+11.02% | Revisions=+20% | GrowthEPS=+16.7% | GrowthRev=+8.0%
EPS next Year (2027-12-31): EPS=3.18 | Chg30d=+1.45% | Revisions=+20% | GrowthEPS=+0.2% | GrowthRev=+12.8%
[Analyst] Revisions Ratio: +20%